Advanced Therapy Manufacturing for Start-Ups: The Need for a Next Generation CDMO

The cell and gene therapy sector is booming, with over 90 new trials in 2023 and nearly 4,000 treatments in progress. Small biotechs, often university spin-offs, are driving innovation but lack the resources for in-house manufacturing, leading 75% to partner with CDMOs. Yet, these start-ups have specific early-stage development needs not fully met by current CDMOs, necessitating a new model that offers tailored expertise and flexible pricing to support their unique challenges in this rapidly evolving field.